Ceftazidime-avibactam for the treatment of infections caused by carbapenem-resistant Gram-negative pathogens in Chinese patients: A phase IV, multi-centre, open-label study
Ceftazidime-avibactam for the treatment of infections caused by carbapenem-resistant Gram-negative pathogens in Chinese patients: A phase IV, multi-centre, open-label study. // International Journal of Antimicrobial Agents. – URL: https://www.sciencedirect.com/science/article/pii/S0924857926003171?dgcid=rss_sd_all
Ceftazidime-avibactam for the treatment of infections caused by carbapenem-resistant Gram-negative pathogens in Chinese patients: A phase IV, multi-centre, open-label study. International Journal of Antimicrobial Agents. https://www.sciencedirect.com/science/article/pii/S0924857926003171?dgcid=rss_sd_all
“Ceftazidime-avibactam for the treatment of infections caused by carbapenem-resistant Gram-negative pathogens in Chinese patients: A phase IV, multi-centre, open-label study.” International Journal of Antimicrobial Agents.
@article{article49456,
title = {Ceftazidime-avibactam for the treatment of infections caused by carbapenem-resistant Gram-negative pathogens in Chinese patients: A phase IV, multi-centre, open-label study},
journal = {International Journal of Antimicrobial Agents},
url = {https://www.sciencedirect.com/science/article/pii/S0924857926003171?dgcid=rss_sd_all}
}